Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC
AUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de...
BELTSVILLE, Md., April 19, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
Ankyra Therapeutics is bringing on outside expertise to support its bid to unlock the power of cytokines. Working with scientists at the National Cancer Institute (NCI), the Tillman Gerngross, Ph.D., co-founded biotech will carry out basic, translational and clinical research on candidates including its lead IL-12 prospect.